MariMed (MariMed) Risk Assessment

View and export this data going back to 2012. Start your Free Trial

What is MariMed Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of MariMed is: High Risk: High uncertainty.

Competitive Comparison of MariMed's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MariMed's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Risk Assessment distribution charts can be found below:

* The bar in red indicates where MariMed's Risk Assessment falls into.

MariMed (OTCPK:MRMD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

MariMed Risk Assessment Related Terms

Thank you for viewing the detailed overview of MariMed's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

MariMed (MariMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

MRMD:Canada

Address

10 Oceana Way, Floor 2, Norwood, MA, USA, 02062

Website

https://www.marimedinc.com

MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.

Executives

Jon R Levine	10 percent owner	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw	officer: Chief Operating Officer	C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker	director	C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare	officer: Chief Financial Officer	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d.	director	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin	director	11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman	director	310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman	director	145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc.	director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY	11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan	officer: CFO, VICE PRESIDENT	11 ROYAL RD, BROOKLINE MA 02445